MiMedx To Present At The 16th Annual Needham Healthcare Conference

Friday, March 24, 2017 General News
Email Print This Page Comment
Font : A-A+

MARIETTA, Ga., March 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical

company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sectors of healthcare, announced today  that it will present at the Needham Healthcare Conference in
New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP and Chief Commercialization Officer, and Mark Landy, VP, Strategic Initiatives, are scheduled to present on Tuesday, April 4, 2017, 9:20 a.m. eastern time, at the Westin New York Grand Central.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biopharmaceutical and biomaterial products processed from donated placental tissues. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.  MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-the-16th-annual-needham-healthcare-conference-300429172.html

SOURCE MiMedx Group, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook